Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$198 Mln
P/E Ratio
--
P/B Ratio
6.7
Industry P/E
--
Debt to Equity
0.17
ROE
-1.54 %
ROCE
-131.37 %
Div. Yield
0 %
Book Value
0.11
EPS
-0.2
CFO
$-314.65 Mln
EBITDA
$-422.89 Mln
Net Profit
$-349.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ocugen (OCGN)
| -8.46 | 21.88 | -5.51 | -41.05 | -32.54 | 18.02 | -47.75 |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Ocugen (OCGN)
| 39.62 | -55.77 | -71.43 | 148.63 | 251.92 | -90.20 | -95.61 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 10,135.98 | 20.78 | 23.13 | |
| 302.88 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene... therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Address: 11 Great Valley Parkway, Malvern, PA, United States, 19355 Read more
Co-Founder, CEO & Chairman
Dr. Shankar Musunuri M.B.A., Ph.D.
Co-Founder, CEO & Chairman
Dr. Shankar Musunuri M.B.A., Ph.D.
Headquarters
Malvern, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ocugen Inc (OCGN) stood at $ 82 Mln as on 31-Dec-24
The share price of Ocugen Inc (OCGN) is $0.74 (NASDAQ) as of 24-Apr-2025 16:24 EDT. Ocugen Inc (OCGN) has given a return of -32.54% in the last 3 years.
Ocugen Inc (OCGN) has a market capitalisation of $ 198 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ocugen Inc (OCGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ocugen Inc (OCGN) and enter the required number of quantities and click on buy to purchase the shares of Ocugen Inc (OCGN).
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Address: 11 Great Valley Parkway, Malvern, PA, United States, 19355
The CEO & director of Dr. Shankar Musunuri M.B.A., Ph.D.. is Ocugen Inc (OCGN), and CFO & Sr. VP is Dr. Shankar Musunuri M.B.A., Ph.D..
There is no promoter pledging in Ocugen Inc (OCGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Ocugen Inc. (OCGN) | Ratios |
|---|---|
|
Return on equity(%)
|
-154.01
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-1333.02
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ocugen Inc (OCGN) was $0 Mln.
$0.02
(
